

Application No.: 09/905,810  
Amendment dated November 21, 2003  
In response to Examiner's Office Action dated May 21, 2003

**AMENDMENTS TO THE CLAIMS**

Please amend claims 1, 4 and 23.

This Listing of Claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

Claim 1 (currently amended): A method for blocking the development or treating or reducing the severity or effects of a Graft-Versus-Host Disease or an organ transplant failure resulting from graft rejection in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of ~~an anti-TWEAK polypeptide~~ a monoclonal antibody that binds specifically to a TWEAK ligand of SEQ ID NO:2 and a pharmaceutically acceptable carrier.

Claims 2-3 (previously canceled).

Claim 4 (currently amended): The method according to claim 1, wherein the animal is ~~mammalian~~ a mammal.

Claim 5 (original): The method according to claim 4, wherein the mammal is human.

Application No.: 09/905,810

Amendment dated November 21, 2003

In response to Examiner's Office Action dated May 21, 2003

Claim 6 (previously withdrawn): The method according to claim 1 or 2, wherein the TWEAK blocking agent comprises a soluble TWEAK receptor having a ligand binding domain that can selectively bind to a surface TWEAK ligand.

Claim 7 (previously withdrawn): The method of claim 6, wherein the soluble TWEAK receptor comprises a human immunoglobulin IgG domain.

Claim 8 (previously withdrawn): The method of claim 7, wherein the human immunoglobulin IgG domain comprises regions responsible for specific antigen binding.

Claim 9 (previously withdrawn): The method according to claim 1 or 2, wherein the antibody directed against the TWEAK receptor comprises a monoclonal antibody.

Claims 10-11 (previously canceled).

Claim 12 (previously amended): The method according to claim 1, wherein said Graft-Versus-Host Disease or said organ transplant failure is caused by a Th1 cell-mediated immune response.

Claim 13 (previously amended): The method according to claim 1, wherein said Graft-Versus-Host Disease or said organ transplant failure is caused by a Th2 cell-mediated immune response.

Claim 14 (previously amended): The method according to claim 1, wherein said Graft-Versus-Host Disease or said organ transplant failure is caused by a combination of a Th1 and a Th2 cell-mediated immune response.

Claim 15 (previously withdrawn): The method according to claim 2, wherein the TWEAK blocking agent comprises a monoclonal antibody directed against the TWEAK receptor.

Claims 16-22 (previously canceled).

Claim 23 (currently amended): The method according to claim 1, wherein said ~~anti-TWEAK polypeptide~~ monoclonal antibody that binds specifically to a TWEAK ligand of SEQ ID NO:2 is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody; and

Application No.: 09/905,810

Amendment dated November 21, 2003

In response to Examiner's Office Action dated May 21, 2003

(c) a recombinant antibody.